Description:

ODM derived from http://clinicaltrials.gov/show/NCT00332709

Lien:
http://clinicaltrials.gov/show/NCT00332709
Mots-clés:
Versions (4)
  1. 11/12/2013 11/12/2013 - Martin Dugas
  2. 14/04/2014 14/04/2014 - Julian Varghese
  3. 02/09/2021 02/09/2021 -
  4. 20/09/2021 20/09/2021 -
Téléchargé le:

20 septembre 2021

DOI:
Pour une demande vous connecter.
Licence :
Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility NCT00332709 Osteoporosis. Postmenopausal

Allemand Anglais
Détails

Eligibility

1 Formulaires  
  1. StudyEvent: Eligibility
    1. Eligibility
Einschlusskriterien
Alter 18 Jahre und älter
Compliant postmenopausal women with primary operable breast cancer after 4 to 6 years of therapy with tamoxifen (end of tamoxifen therapy within last 6 months)
ECOG Status
Patients without severe osteoporosis at study entry
No evidence of relapse at the time of randomization
Adequate function of bone marrow, kidney, and liver
Ausschlusskriterien
Estrogen- and progesterone-receptor status negative or unknown
Completion of adjuvant tamoxifen therapy more than 6 months prior to study start
Inflammatory Breast Carcinoma, Mastitis carcinomatosa
Current/active dental problems including infection of the teeth or jawbone, dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw, of exposed bone in the mouth, or of slow healing after dental procedures
Recent (within 6 weeks) or planned dental or jaw surgery
History of diseases with influence on bone metabolism such as Paget's disease and primary overactive parathyroid
Prior or concomitant therapies: chemotherapy within the last 12 months, intravenous or oral bisphosphonates, systemic corticosteroids, anabolic steroids or growth hormones, Tibolone, parathyroid hormone, systemic sodium fluoride or any drugs known to affect the skeleton (such as calcitonin, mithramycin, or gallium nitrate)
Patients with previous or concomitant cancers (not breast cancer) within the past 5 years EXCEPT adequately treated basal or squamous cell skin cancers or in situ cancer of the cervix. Patients with previous other cancer(s) must have been disease-free for at least 5 years.
Patients currently receiving oral bisphosphonates must discontinue these at least 3 weeks prior to study start.
Retour au début de la page

Similar models

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial